A Hybrid ELISA combines recombinant VlsE protein and C6 peptide to improve early Lyme detection without sacrificing specificity.
Low intracellular delivery from polymers and cationic liposomes is addressed with cyclic peptide vehicles that promote endosomal escape.
Specific residues and non-natural cyclic peptides target KRAS while minimizing interaction with HRAS and NRAS in RAS-mutant cancer cells.
PD-L1-binding macrocyclic compounds block PD-L1 interactions with PD-1 and CD80 to counter immune suppression and restore T-cell activation.
An intracellularly cleavable oligopeptide helps a branched PEG derivative retain blood stability while preventing cell vacuolation.